Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
